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 HbA1c has a low sensitivity in the diagnosis of cystic fibrosis-related 
diabetes (CFRD) and the oral glucose tolerance test (OGTT) is the 
current preferred method of diagnosis. 
 There is an association between HbA1c and microvascular damage in 
CFRD but the extent of this is not fully established. 
What are the new findings?  
 HbA1c level above 37 mmol/mol (5.5%) is associated with the 
development of a positive OGTT.  
 Higher HbA1c levels are associated with severe forms of retinopathy 
How might this impact on clinical practice in the foreseeable future? 
 HbA1c level greater than 37mmol/mol (5.5%), in an individual who does not 
have the formal diagnosis of CFRD, would be an indication for closer 
scrutiny of their glycaemic control.  
Author contributions:  The study was designed by MC and FSW and 
supervised by FSW.  MC, PM and PT analysed data.  MC and FSW drafted 
the article and PM, PT, JD, DL, LG and RIK revised the article.  All authors 
approved the final version of the manuscript.  MC is the guarantor of this 
study and had full access to all the data, taking full responsibility for the 











To examine glycated haemoglobin (HbA1c) as a predictor of risk for future 
development of Cystic Fibrosis-Related Diabetes (CFRD) and assess the 
association with the development of retinopathy in CFRD 
 
Research and Methods 
A 7-year retrospective longitudinal study was conducted in 50 adults with CF 
comparing oral glucose tolerance test results with HbA1c values in predicting 
the development of CFRD. Retinal screening data were also compared to 
HbA1c measurements to assess microvascular outcome.  
  
Results 
An HbA1c value greater than or equal to 37mmol/mol (5.5%) (hazard ratio 
3.49,CI 1.5-8.1) was significantly associated with the development of 
dysglycaemia as defined by the OGTT over a 7-year period. Severity of 
diabetic retinopathy was associated with a higher HbA1c and longer duration 
of CFRD.  
 
Conclusion 
There is a link between HbA1c level and the future development of 
dysglycaemia in CF based on OGTT, as well as microvascular outcomes. 
Although current guidance does not advocate the use of HbA1c as a 
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diagnostic tool in CFRD, it may be of clinical use in determining individuals at 
risk of future development of CFRD. 
 
Research in context 
Keywords 




Cystic Fibrosis Related Diabetes (CFRD) is a condition that is distinct from 
Type 1 and Type 2 diabetes mellitus. Dysglycaemia in Cystic Fibrosis (CF) is 
associated with a decline in pulmonary function and body mass index (BMI)  
[1,2]. This is particularly important as decline in forced expiratory volume in 1 
s (FEV1) and BMI are associated with increased mortality in CF [3]. Thus, 
early detection of dysglycaemia may help to reduce the rate of decline in 
pulmonary function and microvascular disease. However, controversy 
remains over the methods used to screen for CFRD [4].  
Currently, annual oral glucose tolerance testing (OGTT) is undertaken in 
many adult CF centres as part of the screening process of CFRD [5]. The 
OGTT is classified as normal for an individual with CF when the fasting and 2-
hour values are within reference range, as defined by WHO [6]. The issue 
regarding the use of the OGTT in the diagnosis of CFRD is widely debated. It 
examines glucose levels at two time points. This does not necessarily 
correlate with clinical outcome in CF as there is a deterioration in an 
individual’s clinical status prior to diagnosis [2,7]. The glycaemic state in a CF 
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individual is highly fluctuant [8]. Thus, any high glucose which is observed but 
not demonstrable by the two-hour time points on an OGTT could lead to a 
negative impact on pulmonary function in an individual with CF [7].  
Glycated Haemoglobin (HbA1c) reflects glycaemic control over a period of 
time. This may have some advantages over the OGTT. The use of HbA1c as a 
screening tool in CFRD is controversial. Current UK guidance does not 
recommend using HbA1c as part of the screening process for CFRD as the 
value is often within the normal range despite an OGTT diagnostic of CFRD 
[9]. Individuals with CF can have increased red cell breakdown and iron 
deficiency anaemia, which can affect interpretation of HbA1c [10]. However 
there is limited evidence on whether HbA1c can provide guidance in 
determining whether a person with CF may develop dysglycaemia and require 
further investigation [11]. It is a test that can be taken on a random basis, and 
thus can potentially reduce the burden of annual OGTT, a cumbersome test 
that requires individuals to travel from long distances in a fasting state, to a 
CF centre. In light of the debate surrounding the OGTT, we explored the 
possibility of whether the HbA1c can be an adjunctive tool in the prediction of 
individuals who may later develop CFRD.  
 
Objective 
To compare OGTT test results and HbA1c measurements in people with adult 
CF attending the All Wales Adult Cystic Fibrosis Centre and correlate this with 
retinal screening data in CFRD. 
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Research Design and Methods 
A retrospective longitudinal study was performed from the beginning of 2006–
end of 2012, a period of 7 years.  In total, 50 people were followed between 
this period.  Fasting plasma glucose and 2-hour post-prandial glucose levels 
were analysed in individuals who underwent an OGTT as part of their routine 
annual review. The diagnosis of CFRD using OGTT was based on WHO 
criteria [6].  
A corresponding HbA1c level was measured using high performance liquid 
chromatography (Tosoh G8 Automated Glycohaemoglobin Analyser), Tosoh 
Bioscience (Tokyo, Japan). 
Statistical analysis 
The TRIPOD guidelines, were followed in the design and analysis of the study 
[12]. R statistical environment and SPSS 18 were used in statistical analysis. 
Pearson’s chi-squared was used to assess categorical data. The Mann-
Whitney U test was used for non-parametric data. Receiver operating 
characteristics (ROC) curves were generated as part of sensitivity and 
specificity assessment. The log rank test was used to estimate the predictive 
value of HbA1c in the development of CFRD and CF with impaired glucose 
tolerance (CF dysglycaemia), which was the primary outcome of the study.  
Results 
Of the 71 individuals with CF who had a recorded OGTT, 50 individuals were 
identified who initially had CF with normal glucose tolerance  based on OGTT 
in 2006. These were followed up from over the 7 years from the beginning of 
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2006. In the remaining 21 individuals, five had CFRD and sixteen had CF with 
impaired glucose tolerance. The mean age of the 50 individuals with CF with 
normal glucose tolerance was 26 years (± 6.5 SD); FEV1 percentage 
predicted mean was 68 (± 25 SD) and mean BMI was 22.6 kg m2. The mean 
HbA1c was 38mmol/mol (5.6%) (Table 1). Of these 50 individuals, 18 had a 
HbA1c less than 37mmol/mol (5.5%) and 32 individuals had a HbA1c greater 
than or equal to 37mmol/mol (5.5%). In the follow up period, 4 individuals with 
a HbA1c <37mmol/mol (5.5%) developed dysglycaemia in the form of impaired 
glucose tolerance or CFRD. In the group with a HbA1c ≥37mmolmol (5.5%), 
18 individuals developed dysglyceamia.  
A ROC curve was generated to determine the strength of the association 
between the value of HbA1c compared to 2-hour plasma glucose in the OGTT 
in the development of diabetes over the 7-year period. The median time to 
diagnosis was 4 years.  The area under the fitted ROC curve was 0.76 for 
HbA1c in 2006 (p=0.012). To have a test of higher sensitivity and moderate 
specificity, an HbA1c level ≥ 37mmol/mol (5.5%) would have 100% sensitivity 
but 45% specificity, in terms of prediction of development of CFRD, based on 
CF Trust diagnostic criteria, with OGTT data as the outcome. The area under 
the curve was greater when using HbA1c as the baseline variable compared to 
fasting plasma glucose (area under the curve value of 0.645).  This suggests 
that HbA1c level is closely associated with the development of CFRD, using 
OGTT as the outcome diagnostic test.  
The predictive value of HbA1c level ≥37mmol/mol (5.5%) for the future 
development of CFRD and impaired glucose tolerance in the 50 individuals, 
who were initially CF with normal glucose tolerance in 2006, was examined 
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using a Log rank test (Figure 1).  The time to development of the first 
abnormal OGTT between 2006 and 2012 was investigated.  The analysis 
revealed that individuals with HbA1c ≥37mmol/mol (5.5%) were significantly 
more likely to develop an abnormal OGTT (p=0.009) over a 7-year period 
(Hazard ratio 3.49; 95%CI 1.5 to 8.1).   
A separate review of diabetic retinopathy was undertaken. This was based on 
reports from the diabetes retinal screening service in Wales. Of 43 individuals 
with CFRD who underwent retinal screening between 2010 and 2012,19 
individuals (44%) had evidence of diabetic retinopathy, based on their most 
recent retinal screen (mean HbA1c 68 mmol/mol (8.4% ± 1.4%)).  This ranged 
from mild non-proliferative diabetic retinopathy to clinically significant macular 
oedema. Of the 24 individuals with no diabetic retinopathy, the mean HbA1c 
was 54mmol/mol (7.1%±1%SD). This difference was significant (p<0.05). 
Individuals with more severe forms of diabetic retinopathy were older, 
compared to those individuals who had no diabetic retinopathy or non-
proliferative retinopathy. They also had greater HbA1c levels (P=0.038) and a 
larger percentage had a trend to a longer duration of CFRD (over 5 years), 
although this was not statistically significant.  
Discussion 
Our longitudinal retrospective study identifies a link between glycated 
haemoglobin and future glycaemic status in CF and microvascular outcome. 
Although current guidance does not recommend the use of HbA1c as a 
screening tool in CFRD and our study also does not advocate this, there is 
relatively little information concerning the use of HbA1c in prediction of the 
 9 
development of CFRD. Glycated haemoglobin is currently recommended for 
monitoring purposes in individuals who already have CFRD, as an overall 
assessment of glycaemic control [5]. However, our findings suggest that 
HbA1c could also be used in assessing individuals at risk of developing CFRD, 
in addition to the OGTT, rather than solely in monitoring once a diagnosis has 
been made. An HbA1c level of 37mmol/mol (5.5%) and above, would aid in 
determining who is at risk of developing CFRD and thus identify a proportion 
of individuals who would benefit from additional testing to identify 
dysglycaemia.   This could be advocated at times of infective exacerbations or 
if weight loss is noted. 
Glycated haemoglobin as a screening tool has been examined in a number of 
studies. A HbA1c ≥ 5.8%(40mmol/mol) was advocated as a cut off level which 
was predictive of a positive OGTT by Burgess et al [11]. In contrast Boudreau 
et al, demonstrated a HbA1c level ≥5.8%(40mmol/mol) was limited by low 
sensitivity and specificity (68.2 and 60.5% respectively) when compared to 
OGTT results [13]. Small-scale studies examining the use of HbA1c also do 
not support HbA1c as a sole screening tool in CFRD, although they have used 
different levels of HbA1c in their research [14].   
Based on our investigation, we do not support the use of HbA1c to screen for 
CFRD, but rather suggest that a HbA1c above 37mmol/mol (5.5%) is 
associated with a high risk of development of CFRD and warrants closer 
scrutiny.  We would recommend further studies in continuous glucose 
monitoring (CGM) to document the presence of dysglycaemia for those 
individuals with a raised HbA1c. Although our study did not compare CGM with 
HbA1c, there is evidence of a correlation between the two measurements [15].  
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This may reveal a population, not diagnosed by the conventional OGTT, who 
could benefit from receiving insulin treatment. The fluctuating glycaemic 
profile in CF, suggests that a normal OGTT does not necessarily exclude 
CFRD and dysglycaemia. Additionally, there may be evidence of a 
deterioration in clinical status prior to a formal diagnosis of CFRD. Thus, 
HbA1c may be a useful adjunctive tool, to highlight those with underlying 
dysglycaemia, who would benefit from treatment. Currently, CGM is 
undertaken in many CF centres in the UK and can aid clinicians in 
determining underlying dysglycaemia, although not validated for diagnostic 
purposes.  
This study was based on an adult population; thus we cannot translate our 
results to the paediatric CF population.  However, it may highlight a population 
who may benefit from treatment.  Administration of insulin is the mainstay of 
therapy in CFRD, which reverses weight loss in CFRD and potentially 
improves survival [16]. Insulin in the pre-diabetes stage may also improve 
clinical outcome in CF although studies examining this have been small scale 
[17]. 
In our study, we are limited by the small population size as OGTT was 
introduced in 2005 in our CF centre. Thus, we cannot apply our findings 
strictly to current clinical practice and large, longitudinal population studies are 
required to validate our findings.  We have assessed glycaemic control over a 
7-year time frame, which has advantages over recent studies that have 
observed larger populations of individuals with CF but over a shorter time 
duration [12,13]. A further limitation is that we did not measure haematological 
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parameters in our population, which could affect interpretation of our findings 
in HbA1c.  
We have previously shown microvascular damage in the form of retinopathy is 
evident in CFRD and associated with increasing HbA1c although this does not  
reflect the true extent of the condition due to poor uptake of retinal screening 
in CFRD [18].  The presence of more severe retinopathy in some individuals 
with a relatively short duration of CFRD attests to the possibility that 
dysglycaemia has been present for a longer duration.  Schwarzenberg et al 
identified the presence of any form of diabetic retinopathy in 16% of CFRD 
individuals with fasting hyperglycaemia [19]. The difference in prevalence 
compared to our population may be related to the screening process. The 
findings from our study highlight the impact of CFRD on microvascular 
outcome, which is more prevalent compared to previous study findings [19]. 
There have been reports of diabetic retinopathy in individuals who have not 
been diagnosed with CFRD [20]. In our findings, one female had moderate 
diabetic retinopathy but who had CFRD for only 2 years. This conveys the 
importance of the early diagnosis of dysglycaemia in CF. The use of HbA1c 
may allow clinicians to predict the development of CFRD at an early stage 
and allow early screening of microvascular changes.  
  
Early diagnosis and treatment is important to prevent the decline in health of 
the CF population.  We demonstrate that HbA1c is associated with a future risk 
of developing CFRD in individuals with CF within a 7-year time frame, and 
who may thus require increased vigilance in monitoring glycaemic control. 
More longitudinal studies are needed to establish what are the most 
 12 
appropriate diagnostic tests for dysglycaemia in a CF population.  
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Table 1 Clinical characteristics of the 50 individuals based on glycaemic status in 
2006. 
Number of individuals 
within each group 
 
CF-normal glucose tolerance 
N=50 
Gender male and female 29 Male 
21 Female 
Mean age in years (±SD) 26 (±6.5) 
FEV1 % predicted (±SD) 68 (±25) 










Figure 1 – Survival curve displaying the time to development of 
CFRD/CF with impaired glucose tolerance based on HbA1c. The graph 
illustrates the time to development of dysglycaemia (CFRD/CF-impaired 
glucose tolerance) in individuals with HbA1c ≥37 mmol/mol (5.5%, dotted line) 
compared to individuals with HbA1c < 37 mmol/mol (5.5%, solid line).  The 
number remaining at risk at 2, 4 and 6 years is shown below the graph.  At the 
end point of the observation, at 7 years, 14/18 individuals with HbA1c < 37 
mmol/mol (5.5%) remained at risk, compared with 14/32 individuals with 
HbA1c ≥ 37 mmol/mol (5.5%). Analysis by log rank test, p=0.009.  
 
 
 
